Margaret Hamburg, M.D.
Co-president, InterAcademy Partnership
Margaret A. Hamburg, MD, Joins NTI as Interim Vice President for NTI | bio
NTI board member Margaret A. Hamburg, MD, is joining NTI’s leadership to serve as interim vice president of the NTI | bio program in February. Hamburg, an internationally recognized leader in public health and medicine, replaces Beth Cameron, PhD, who has moved to the White House to rebuild the National Security Council’s Office of Global Health Security and Biodefense and advance the Biden Administration’s agenda on global health security.
Hamburg’s relationship with NTI goes back to its launch in 2001, when she was named as the organization’s founding senior scientist and biological program vice president. She went on to become commissioner of the Food and Drug Administration and foreign secretary of the National Academy of Medicine.
Hamburg joined NTI’s Board of Directors in 2017.
Stay Informed
Sign up for our newsletter to get the latest on nuclear and biological threats.
More News
NTI and The Elders Convene Intergenerational Dialogue to Address Biological Risks
Policy decisions made today will shape the world's ability to prevent and respond to biological threats for decades to come. Meeting that challenge will require more than expert analysis. It will require collaboration across generations of leaders to engage policymakers and the public.
Leaders Urge Targeted Investment to Strengthen African Health Security as Funding Landscape Changes
Ambassadors and officials from African embassies, U.S. government representatives, and health security and philanthropic leaders gathered at NTI on October 7 to discuss how data from the 2026 Africa Health Security Index can guide critical decisions to sustain preparedness across the continent.
U.S. and Chinese Experts Find Common Ground on Guardrails for AI in Biology
NTI | bio and the Center for International Security and Strategy (CISS) at Tsinghua University convened a virtual dialogue on risks at the convergence of artificial intelligence and the life sciences (AIxBio).
